Would Nvax hit break even price $7.63 - Qn to ai (Asking on Piku's behalf)

Novavax (NVAX) Analysis: Key Considerations for Tonight's Price Action

Current Price & Recent Performance

Latest Price (2025-04-24): $7.49 USD (up 19.52% today), with an intraday high of $7.81 and low of $6.99.

Break-Even Target: $7.63 (needs +0.16 USD from current level to reach).

Recent Surge: The stock jumped 19.52% today , driven by news of FDA progress on its COVID-19 vaccine approval.

Catalysts & News

FDA Update (Key Driver): The FDA requested additional clinical data as part of a post-marketing commitment, signaling potential approval for Novavax’s vaccine. This news sparked a 12–19% rally in premarket and intraday trading.

Market Sentiment: Analysts interpret the FDA's request as a constructive step toward full approval, reducing uncertainty about the company’s viability.

Technical & Fundamental Factors

Resistance/Support Levels:

Resistance: $7.79 (recent high on 2025-04-23).

Support: $5.79 (2025-04-23 low).

The stock already breached $7.63 intraday ($7.81 high), indicating bullish momentum.

Volume & Momentum:

Trading Volume: 14.73M shares (elevated activity).

Volume Ratio: 3.49x, suggesting strong buying interest.

Fundamental Weakness:

Negative EPS (-1.23) and ROE (-898.20%) highlight ongoing financial challenges.

Analyst Targets: Mean price target of $17.33 (long-term optimism vs. short-term risks).

Short-Term Outlook

Tonight's Potential: The stock has shown volatility around FDA updates. A retest of the intraday high ($7.81) is possible if bullish sentiment persists in after-hours trading.

Risks: Profit-taking after today’s surge and weak fundamentals could cap gains.

Recommendation

Monitor After-Hours Activity: If buying pressure continues, $7.63 is achievable. Set alerts for price movements.

Caution Advised: The rally is news-driven; fundamentals remain weak. Consider trimming positions if the break-even is hit.

📉 Key Risk Disclosure: Past performance is not indicative of future results. Novavax's financial health and reliance on regulatory approvals pose significant risks. Consult a financial advisor before trading.

@Piku